How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,087 results for

Depo Provera

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1081. Effect of Depo-Provera or Microgynon on the painful crises of sickle cell anemia patients. (Abstract)

Effect of Depo-Provera or Microgynon on the painful crises of sickle cell anemia patients. Forty-three homozygous (SS) female sickle cell anemic patients with a history of at least one painful crisis per month and desiring a reversible contraceptive were administered DMPA/3 months or Microgynon monthly. A third group of 16 surgically sterilized patients served as control. Patients were followed for 1 year to assess possible effects of the contraceptives on the patients' painful crises

1997 Contraception Controlled trial quality: uncertain

1082. Depot medroxyprogesterone (Depo-Provera) and risk of breast cancer. Full Text available with Trip Pro

Depot medroxyprogesterone (Depo-Provera) and risk of breast cancer. To determine whether use of the injectable contraceptive depot medroxyprogesterone acetate (Depo-Provera) affects the risk of breast cancer in women.A population based case-control study.Nationwide community study.891 Women aged 25-54 with newly diagnosed breast cancer were compared with 1864 women selected at random from the electoral rolls.Women were interviewed by telephone about past use of contraceptives and about possible

1989 BMJ : British Medical Journal

1083. Depo-Provera contraceptive may increase risk of cardiovascular disease Full Text available with Trip Pro

Depo-Provera contraceptive may increase risk of cardiovascular disease 12219755 2002 09 26 2013 11 21 1756-1833 325 7363 2002 Sep 07 BMJ (Clinical research ed.) BMJ Depo-Provera contraceptive may increase risk of cardiovascular disease. 513 Bosch Xavier X eng News England BMJ 8900488 0959-8138 0 Contraceptive Agents, Female C2QI4IOI2G Medroxyprogesterone Acetate AIM IM Cardiovascular Diseases chemically induced Contraceptive Agents, Female adverse effects Female Humans Medroxyprogesterone

2002 BMJ : British Medical Journal

1084. Supplementation with vitamin C and/or vitamin B(6) in the prevention of Depo-Provera side effects in adolescents. (Abstract)

Supplementation with vitamin C and/or vitamin B(6) in the prevention of Depo-Provera side effects in adolescents. Depo-Provera-induced menstrual irregularity is believed to be secondary to relative estrogen deficiency. Weight gain associated with this contraceptive method is believed to be due to Depo-Provera's steroid-like appetite stimulation effect and to an altered tryptophan metabolism. We examined whether vitamin C, an important factor in uterine estrogen binding, and vitamin B(6 (...) ), a glucocorticoid antagonist and an important coenzyme in the tryptophan-serotonin pathway, might alleviate menstrual irregularities and weight gain associated with Depo-Provera.Fifty-five adolescent girls (age 16 +/- 1 yr, gyn age 4 +/- 1 yr, body mass index 25.2 +/- 0.9) who decided to initiate Depo-Provera (150 mg intramuscularly every 3 months) were randomly assigned to one of four groups (group 1: vitamin B(6) 50 mg plus placebo pill/day; group 2: vitamin C 500 mg plus placebo pill/day; group 3: vitamin B

2002 Journal of pediatric and adolescent gynecology Controlled trial quality: uncertain

1085. Pregnancies diagnosed during Depo-Provera use. (Abstract)

Pregnancies diagnosed during Depo-Provera use. We conducted a review of contraceptive failures among women using Depo-Provera (depot medroxyprogesterone acetate), using reports to the Insurance Division of Planned Parenthood Federation of America, Inc. Cases were included if the Depo-Provera had been given at a Planned Parenthood center and pregnancy had either been diagnosed by, or reported to, a Planned Parenthood center. There were 402 reports of pregnancy from 1994 through 1998. The crude (...) rate of reported pregnancies was 0.42 pregnancies per 1000 women using Depo-Provera each year. Pregnancy was diagnosed after the first trimester in 46% of women. Seventy-seven women (19.1%) received additional Depo-Provera injections while pregnant. Of the women whose date of conception could be estimated, 113 of 258 (45%) became pregnant after the injection. There was no observed increase in ectopic pregnancy rate, and no fetal anomalies were reported. Although pregnancy during Depo-Provera use

2002 Contraception

1086. Depot-medroxyprogesterone acetate injection (Depo-Provera): a highly effective contraceptive option with proven long-term safety. (Abstract)

Depot-medroxyprogesterone acetate injection (Depo-Provera): a highly effective contraceptive option with proven long-term safety. Depot-medroxyprogesterone acetate (Depo-Provera(R)) is a highly effective, nondaily hormonal contraceptive option that has been available in the United States for a decade, and worldwide for 40 years. Benefits and risks of hormonal therapy are often under scrutiny; however, long-term clinical experience has established the safety of this long-acting contraceptive

2003 Contraception

1087. Depo-Medroxyprogesterone Acetate (DMPA, Depo-Provera) Use With Certain Anti-HIV Drugs in HIV-Infected Women

Depo-Medroxyprogesterone Acetate (DMPA, Depo-Provera) Use With Certain Anti-HIV Drugs in HIV-Infected Women Depo-Medroxyprogesterone Acetate (DMPA, Depo-Provera) Use With Certain Anti-HIV Drugs in HIV-Infected Women - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. Depo-Medroxyprogesterone Acetate (DMPA, Depo-Provera) Use With Certain Anti-HIV Drugs in HIV-Infected Women The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00016601 Recruitment Status : Completed First Posted : August 31, 2001 Last Update

2001 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>